Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.

Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

---

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

Immediate hypersensitivity -- Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability.

Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.

Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care in patients with metabolic or respiratory alkalosis.

The administration of lactate or acetate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency.

Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation.

The intravenous administration of Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection.

The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection.

In patients with diminished renal function, administration of Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) containing sodium or potassium ions may result in sodium or potassium retention.

Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is not for use in the treatment of lactic acidosis.